nach oben

Current Bladder Dysfunction Reports

Erschienen in:

08.01.2021 | BPS/Interstitial Cystitis (D Castro-Diaz and Y Igawa, Section Editors)

Biomarkers for Bladder Pain Syndrome/Interstitial Cystitis

verfasst von: Ana Charrua, Pedro Mendes, Célia Cruz

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

In this manuscript, the literature published in the past 5 years about BPS/IC biomarkers was reviewed. Topics include BPS/IC biomarkers, the classical BPS/IC diagnostic, clinical outcomes as a new concept of BPS/IC phenotyping biomarkers, BPS/IC urinary biomarkers, BPS/IC bladder tissue biomarkers and BPS/IC biomarkers outside the bladder.

Recent Findings

The importance of patients’ phenotyping and sub-grouping emerged as a way of finding new BPS/IC biomarkers and treatment. Also, the use of non-invasive methodologies and of artificial intelligence approaches has been gaining momentum in BPS/IC biomarkers studies.

Summary

Biomarker research points to the need of following an approach based on a systemic theory instead of a bladder-centred theory. Also, the importance of sample size and the choice of controls to validate BPS/IC biomarkers have been elevated.

Fall M, Nordling J, Cervigni M, Dinis Oliveira P, Fariello J, Hanno P, et al. Hunner lesion disease differs in diagnosis, treatment and outcome from bladder pain syndrome: an ESSIC working group report. Scand J Urol. 2020;54(2):91–8.CrossRef

Malde S, Palmisani S, Al-Kaisy A, Sahai A. Guideline of guidelines: bladder pain syndrome. BJU Int. 2018 [cited 2020 Feb 18];122(5):729–43. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29777618.

Jhang J-F, Hsu Y-H, Jiang Y-H, Ho H-C, Kuo H-C. Clinical relevance of bladder histopathological findings and their impact on treatment outcomes among patients with interstitial cystitis/bladder pain syndrome: an investigation of the European Society for the Study of Interstitial Cystitis Histopatholog. J Urol. 2020. https://doi.org/10.1097/JU.0000000000001334.

Taneja R. Current status of oral pentosan polysulphate in bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2020. https://doi.org/10.1007/s00192-020-04517-9.

Garzon S, Laganà AS, Casarin J, Raffaelli R, Cromi A, Sturla D, et al. An update on treatment options for interstitial cystitis. Prz Menopauzalny. 2020;19(1):35–43.PubMedPubMedCentral

Colemeadow J, Sahai A, Malde S. Clinical management of bladder pain syndrome/interstitial cystitis: a review on current recommendations and emerging treatment options. Res Rep Urol. 2020;12:331–43.PubMedPubMedCentral

Marcu I, Campian EC, Tu FF. Interstitial cystitis/bladder pain syndrome. Semin Reprod Med. 2018;36(2):123–35.CrossRef

Charrua A, Pinto R, Birder LA, Cruz F. Sympathetic nervous system and chronic bladder pain: a new tune for an old song. Transl Androl Urol. 2015;4(5):534–42. https://doi.org/10.3978/j.issn.2223-4683.2015.09.06.

• Tripp DA, Nickel JC, Wong J, Pontari M, Moldwin R, Mayer R, et al. Mapping of pain phenotypes in female patients with bladder pain syndrome/interstitial cystitis and controls. Eur Urol. 2012;62(6):1188–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22633363This work reported numerous systemic pain symptoms outside the areas associated with the bladder/pelvic region. It was, possible, the turning point from a bladder centric theory to a systemic centred theory.

10.

Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018;243(3):213–21 Available from: https://pubmed.ncbi.nlm.nih.gov/29405771.CrossRef

11.

van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17900797.CrossRef

12.

Engeler Baranowski AP, Borovicka J, Dinis-Oliveira P, Elneil S, Hughes J, Messelink EJ, van Ophoven A, Reisman Y, Williams AC de CD. Guidelines on chronic pelvic pain. Urology EA of, editor. 2013. p. 132. Available from: http://www.uroweb.org/gls/pdf/25_Chronic_Pelvic_Pain_LR.pdf.

13.

Whitmore KE, Fall M, Sengiku A, Tomoe H, Logadottir Y, Kim YH. Hunner lesion versus non-Hunner lesion interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26 Suppl 1:26–34.CrossRef

14.

Walker SJ, Zambon J, Andersson K-E, Langefeld CD, Matthews CA, Badlani G, et al. Bladder capacity is a biomarker for a bladder centric versus systemic manifestation in interstitial cystitis/bladder pain syndrome. J Urol. 2017;198(2):369–75.CrossRef

15.

Schachar JS, Evans RJ, Parks GE, Zambon J, Badlani G, Walker SJ. Histological evidence supports low anesthetic bladder capacity as a marker of a bladder-centric disease subtype in interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2019;30(11):1863–70.CrossRef

16.

Mazeaud C, Rigaud J, Levesque A, Madec F-X, Le Clerc Q-C, Wack M, et al. Stratification of patients with interstitial cystitis/bladder pain syndrome according to the anatomical bladder capacity. Urology. 2019;123:87–92.CrossRef

17.

•• Chancellor MB, Bartolone SN, Veerecke A, Lamb LE. Crowdsourcing disease biomarker discovery research: The IP4IC study. J Urol. 2018;199(5):1344–50 This work presents crowdsourcing as a way to overcome the problem of low sample number presented by different studies. Also, it presents machine learning algorithm as a tool to study BPS/IC biomarkers.CrossRef

18.

Lamb LE, Janicki JJ, Bartolone SN, Peters KM, Chancellor MB. Development of an interstitial cystitis risk score for bladder permeability. PLoS One. 2017;12(10):e0185686.CrossRef

19.

Vera PL, Preston DM, Moldwin RM, Erickson DR, Mowlazadeh B, Ma F, et al. Elevated urine levels of macrophage migration inhibitory factor in inflammatory bladder conditions: a potential biomarker for a subgroup of interstitial cystitis/bladder pain syndrome patients. Urology. 2018;116:55–62.CrossRef

20.

Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013;111(1):52–8.CrossRef

21.

Tonyali S, Ates D, Akbiyik F, Kankaya D, Baydar D, Ergen A. Urine nerve growth factor (NGF) level, bladder nerve staining and symptom/problem scores in patients with interstitial cystitis. Adv Clin Exp Med. 2018;27(2):159–63.CrossRef

22.

Regauer S, Gamper M, Fehr MK, Viereck V. Sensory hyperinnervation distinguishes bladder pain syndrome/interstitial cystitis from overactive bladder syndrome. J Urol. 2017;197(1):159–66.CrossRef

23.

•• Parker KS, Crowley JR, Stephens-Shields AJ, van Bokhoven A, Lucia MS, Lai HH, et al. Urinary metabolomics identifies a molecular correlate of interstitial cystitis/bladder pain syndrome in a multidisciplinary approach to the study of Chronic Pelvic Pain (MAPP) Research Network Cohort. EBioMedicine. 2016;7:167–74 This work excels the existence of multiple BPS/IC patients phenotype. Although they have focused on etiocholan-3α-ol-17-one sulphate (Etio-S), they lift the veil to other molecules/BPS/IC phenotypes.CrossRef

24.

Jiang Y-H, Jhang J-F, Hsu Y-H, Ho H-C, Wu Y-H, Kuo H-C. Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics. Am J Physiol Ren Physiol. 2020;318(6):F1391–9.CrossRef

25.

Di Capua-Sacoto C, Sanchez-Llopis A, Oconnor JE, Martinez-Romero A, Ruiz-Cerdá JL. Apoptotic effect as biomarker of disease, severity and follow-up in interstitial cystitis. Actas Urol Esp. 2018;42(4):262–6.CrossRef

26.

Argade S, Berecz Z, Su Y, Parsons CL. Increased toxic urinary cations in males with interstitial cystitis: a possible cause of bladder symptoms. World J Urol. 2016;34(12):1685–91.CrossRef

27.

Jiang Y-H, Kuo Y-C, Jhang J-F, Lee C-L, Hsu Y-H, Ho H-C, et al. Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis. Sci Rep. 2020;10(1):15218. https://doi.org/10.1038/s41598-020-72292-0.

28.

Bradley MS, Burke EE, Grenier C, Amundsen CL, Murphy SK, Siddiqui NY. A genome-scale DNA methylation study in women with interstitial cystitis/bladder pain syndrome. Neurourol Urodyn. 2018;37(4):1485–93.CrossRef

29.

Saha SK, Jeon T-I, Bin JS, Kim SJ, Lim KM, Choi YJ, et al. Bioinformatics approach for identifying novel biomarkers and their signaling pathways involved in interstitial cystitis/bladder pain syndrome with Hunner lesion. J Clin Med. 2020;9(6):1935. https://doi.org/10.3390/jcm9061935.

30.

•• Arai T, Fuse M, Goto Y, Kaga K, Kurozumi A, Yamada Y, et al. Molecular pathogenesis of interstitial cystitis based on microRNA expression signature: miR-320 family-regulated molecular pathways and targets. J Hum Genet. 2018;63(5):543–54 This work approaches the importance of using appropriated controls to validate putative biomarkers. In this case, it demonstrated that bladder tissue from cadaveric donors should not be used (or used with extremely caution) as controls for the validation of RNA-related biomarkers.CrossRef

31.

Matthews CA, Eschenroeder A, Badlani G, Evans R, Walker SJ. Evaluation of the efficacy of postmortem human bladder tissue as a normal comparator for case-controlled gene expression studies in urology. Neurourol Urodyn. 2017;36(4):1076–80.CrossRef

32.

Choi D, Han J-Y, Shin JH, Ryu C-M, Yu HY, Kim A, et al. Downregulation of WNT11 is associated with bladder tissue fibrosis in patients with interstitial cystitis/bladder pain syndrome without Hunner lesion. Sci Rep. 2018;8(1):9782.CrossRef

33.

Song M, Lim J, Yu HY, Park J, Chun J-Y, Jeong J, et al. Mesenchymal stem cell therapy alleviates interstitial cystitis by activating Wnt signaling pathway. Stem Cells Dev. 2015;24(14):1648–57.CrossRef

34.

Cho KJ, Lee K-S, Choi JB, Koh JS, Kim JC. Changes in uroplakin expression in the urothelium of patients with ulcerative interstitial cystitis/bladder pain syndrome. Investig Clin Urol. 2020;61(3):304–9.CrossRef

35.

Furuta A, Suzuki Y, Igarashi T, Koike Y, Kimura T, Egawa S, et al. Angiogenesis in bladder tissues is strongly correlated with urinary frequency and bladder pain in patients with interstitial cystitis/bladder pain syndrome. Int J Urol. 2019;26 Suppl 1:35–40.CrossRef

36.

Ma E, Vetter J, Bliss L, Lai HH, Mysorekar IU, Jain S. A multiplexed analysis approach identifies new association of inflammatory proteins in patients with overactive bladder. Am J Physiol Ren Physiol. 2016;311(1):F28–34.CrossRef

37.

Nickel JC, Stephens-Shields AJ, Landis JR, Mullins C, van Bokhoven A, Lucia MS, et al. A culture-independent analysis of the microbiota of female interstitial cystitis/bladder pain syndrome participants in the MAPP Research Network. J Clin Med. 2019;8(3):415. https://doi.org/10.3390/jcm8030415.

38.

Braundmeier-Fleming A, Russell NT, Yang W, Nas MY, Yaggie RE, Berry M, et al. Stool-based biomarkers of interstitial cystitis/bladder pain syndrome. Sci Rep. 2016;6:26083.CrossRef

39.

Charrua A, Pinto R, Taylor A, Canelas A, Ribeiro-da-Silva A, Cruz CD, et al. Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourol Urodyn. 2015;34(5):489–96. https://doi.org/10.1002/nau.22542.

40.

Kim SW, Son HS, Troya IS, Kim JY, Kim MJ, Fraser MO, et al. Autonomic response during bladder hydrodistention reflects the severity of symptoms in patients with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017;36(3):677–82.CrossRef

Titel: Biomarkers for Bladder Pain Syndrome/Interstitial Cystitis
verfasst von: Ana Charrua
Pedro Mendes
Célia Cruz
Publikationsdatum: 08.01.2021
Verlag: Springer US
Erschienen in: Current Bladder Dysfunction Reports / Ausgabe 1/2021
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-020-00626-9

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Biomarkers for Bladder Pain Syndrome/Interstitial Cystitis

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie